Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen

Won Jung Koh, Goohyeon Hong, Su Young Kim, Byeong Ho Jeong, Hye Yun Park, Kyeongman Jeon, O. Jung Kwon, Seung Heon Lee, Chang Ki Kim, SungJae Shin

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Moxifloxacin (MXF) has in vitro and in vivo activity against Mycobacterium avium complex (MAC) in experimental models. However, no data are available concerning its treatment effect in patients with MAC lung disease. The aim of this study was to evaluate the clinical efficacy of an MXF-containing regimen for the treatment of refractory MAC lung disease. Patients with MAC lung disease who were diagnosed between January 2002 and December 2011 were identified from our hospital database. We identified 41 patients who received MXF for>4 weeks for the treatment of refractory MAC lung disease. A total of 41 patients were treated with an MXF-containing regimen because of a persistent positive culture after at least 6 months of clarithromycin- based standardized antibiotic therapy. The median duration of antibiotic therapy before MXF administration was 410 days (interquartile range [IQR], 324 to 683 days). All patients had culture-positive sputum when MXF treatment was initiated. The median duration of MXF administration was 332 days (IQR, 146 to 547 days). The overall treatment success rate was 29% (12/41), and the median time to sputum conversion was 91 days (IQR, 45 to 190 days). A positive sputum acid-fast-bacillus smear at the start of treatment with MXF-containing regimens was an independent predictor of an unfavorable microbiological response. Our results indicate that MXF may improve treatment outcomes in about one-third of patients with persistently culturepositive MAC lung disease who fail to respond to clarithromycin-based standardized antibiotic treatment. Prospective studies are required to assess the clinical efficacy of MXF treatment for refractory MAC lung disease.

Original languageEnglish
Pages (from-to)2281-2285
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume57
Issue number5
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

Mycobacterium avium Complex
Lung Diseases
Sputum
Therapeutics
Clarithromycin
Anti-Bacterial Agents
moxifloxacin
Bacillus
Theoretical Models
Databases
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Koh, Won Jung ; Hong, Goohyeon ; Kim, Su Young ; Jeong, Byeong Ho ; Park, Hye Yun ; Jeon, Kyeongman ; Kwon, O. Jung ; Lee, Seung Heon ; Kim, Chang Ki ; Shin, SungJae. / Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. In: Antimicrobial agents and chemotherapy. 2013 ; Vol. 57, No. 5. pp. 2281-2285.
@article{ce71c342e2dc4228b09a6bf89bba6696,
title = "Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen",
abstract = "Moxifloxacin (MXF) has in vitro and in vivo activity against Mycobacterium avium complex (MAC) in experimental models. However, no data are available concerning its treatment effect in patients with MAC lung disease. The aim of this study was to evaluate the clinical efficacy of an MXF-containing regimen for the treatment of refractory MAC lung disease. Patients with MAC lung disease who were diagnosed between January 2002 and December 2011 were identified from our hospital database. We identified 41 patients who received MXF for>4 weeks for the treatment of refractory MAC lung disease. A total of 41 patients were treated with an MXF-containing regimen because of a persistent positive culture after at least 6 months of clarithromycin- based standardized antibiotic therapy. The median duration of antibiotic therapy before MXF administration was 410 days (interquartile range [IQR], 324 to 683 days). All patients had culture-positive sputum when MXF treatment was initiated. The median duration of MXF administration was 332 days (IQR, 146 to 547 days). The overall treatment success rate was 29{\%} (12/41), and the median time to sputum conversion was 91 days (IQR, 45 to 190 days). A positive sputum acid-fast-bacillus smear at the start of treatment with MXF-containing regimens was an independent predictor of an unfavorable microbiological response. Our results indicate that MXF may improve treatment outcomes in about one-third of patients with persistently culturepositive MAC lung disease who fail to respond to clarithromycin-based standardized antibiotic treatment. Prospective studies are required to assess the clinical efficacy of MXF treatment for refractory MAC lung disease.",
author = "Koh, {Won Jung} and Goohyeon Hong and Kim, {Su Young} and Jeong, {Byeong Ho} and Park, {Hye Yun} and Kyeongman Jeon and Kwon, {O. Jung} and Lee, {Seung Heon} and Kim, {Chang Ki} and SungJae Shin",
year = "2013",
month = "5",
day = "1",
doi = "10.1128/AAC.02281-12",
language = "English",
volume = "57",
pages = "2281--2285",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

Koh, WJ, Hong, G, Kim, SY, Jeong, BH, Park, HY, Jeon, K, Kwon, OJ, Lee, SH, Kim, CK & Shin, S 2013, 'Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen', Antimicrobial agents and chemotherapy, vol. 57, no. 5, pp. 2281-2285. https://doi.org/10.1128/AAC.02281-12

Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. / Koh, Won Jung; Hong, Goohyeon; Kim, Su Young; Jeong, Byeong Ho; Park, Hye Yun; Jeon, Kyeongman; Kwon, O. Jung; Lee, Seung Heon; Kim, Chang Ki; Shin, SungJae.

In: Antimicrobial agents and chemotherapy, Vol. 57, No. 5, 01.05.2013, p. 2281-2285.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen

AU - Koh, Won Jung

AU - Hong, Goohyeon

AU - Kim, Su Young

AU - Jeong, Byeong Ho

AU - Park, Hye Yun

AU - Jeon, Kyeongman

AU - Kwon, O. Jung

AU - Lee, Seung Heon

AU - Kim, Chang Ki

AU - Shin, SungJae

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Moxifloxacin (MXF) has in vitro and in vivo activity against Mycobacterium avium complex (MAC) in experimental models. However, no data are available concerning its treatment effect in patients with MAC lung disease. The aim of this study was to evaluate the clinical efficacy of an MXF-containing regimen for the treatment of refractory MAC lung disease. Patients with MAC lung disease who were diagnosed between January 2002 and December 2011 were identified from our hospital database. We identified 41 patients who received MXF for>4 weeks for the treatment of refractory MAC lung disease. A total of 41 patients were treated with an MXF-containing regimen because of a persistent positive culture after at least 6 months of clarithromycin- based standardized antibiotic therapy. The median duration of antibiotic therapy before MXF administration was 410 days (interquartile range [IQR], 324 to 683 days). All patients had culture-positive sputum when MXF treatment was initiated. The median duration of MXF administration was 332 days (IQR, 146 to 547 days). The overall treatment success rate was 29% (12/41), and the median time to sputum conversion was 91 days (IQR, 45 to 190 days). A positive sputum acid-fast-bacillus smear at the start of treatment with MXF-containing regimens was an independent predictor of an unfavorable microbiological response. Our results indicate that MXF may improve treatment outcomes in about one-third of patients with persistently culturepositive MAC lung disease who fail to respond to clarithromycin-based standardized antibiotic treatment. Prospective studies are required to assess the clinical efficacy of MXF treatment for refractory MAC lung disease.

AB - Moxifloxacin (MXF) has in vitro and in vivo activity against Mycobacterium avium complex (MAC) in experimental models. However, no data are available concerning its treatment effect in patients with MAC lung disease. The aim of this study was to evaluate the clinical efficacy of an MXF-containing regimen for the treatment of refractory MAC lung disease. Patients with MAC lung disease who were diagnosed between January 2002 and December 2011 were identified from our hospital database. We identified 41 patients who received MXF for>4 weeks for the treatment of refractory MAC lung disease. A total of 41 patients were treated with an MXF-containing regimen because of a persistent positive culture after at least 6 months of clarithromycin- based standardized antibiotic therapy. The median duration of antibiotic therapy before MXF administration was 410 days (interquartile range [IQR], 324 to 683 days). All patients had culture-positive sputum when MXF treatment was initiated. The median duration of MXF administration was 332 days (IQR, 146 to 547 days). The overall treatment success rate was 29% (12/41), and the median time to sputum conversion was 91 days (IQR, 45 to 190 days). A positive sputum acid-fast-bacillus smear at the start of treatment with MXF-containing regimens was an independent predictor of an unfavorable microbiological response. Our results indicate that MXF may improve treatment outcomes in about one-third of patients with persistently culturepositive MAC lung disease who fail to respond to clarithromycin-based standardized antibiotic treatment. Prospective studies are required to assess the clinical efficacy of MXF treatment for refractory MAC lung disease.

UR - http://www.scopus.com/inward/record.url?scp=84876249568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876249568&partnerID=8YFLogxK

U2 - 10.1128/AAC.02281-12

DO - 10.1128/AAC.02281-12

M3 - Article

C2 - 23478956

AN - SCOPUS:84876249568

VL - 57

SP - 2281

EP - 2285

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -